BioWorld: The Daily Biopharmaceutical and Medical Technology …
WEBAkeso scores two new China approvals. Akeso Pharmaceuticals Inc. scored two approvals from China’s National Medical Products Administration on Sept. 30 before the long Labor Day holiday – one for its PCSK9... More in BioWorld Asia. Daily news and analysis of the global biotechnology, pharmaceutical and medical technology industries.
BioWorld: The Daily Biopharmaceutical News Source
WEB2 days ago · Today's news in brief. The U.S. FDA’s approval of yet another indication for Dupixent (dupilumab), partnered between Regeneron Pharmaceuticals Inc. and Sanofi SA, could mean another $6.4 billion-plus in sales by the end of the decade. Regulators cleared the drug as an add-on maintenance treatment for chronic obstructive pulmonary disease ...
FDA clears Vitti's allogenic exosomal product for primary ovarian ...
WEBOct 19, 2022 · As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists (GLP-1RA) market for diabetes and...
MK-5661, a potent Nav1.8 inhibitor with promising safety and
WEBApr 4, 2024 · MK-5661, a potent Nav1.8 inhibitor with promising safety and low oral dose predictions. Discovery of novel Nav1.8 inhibitors capable of achieving high levels of target modulation at low oral doses for the potential treatment of pain was reported by Merck & Co. Inc. Nine years on from securing $3.84 million for a phase I clinical trial to test ...
Degron, Takeda bind $1.2B deal for molecular glue degraders
WEBMay 23, 2024 · Shanghai- and San Diego-based Degron Therapeutics Inc. secured a potential $1.2 billion deal with Tokyo-headquartered Takeda Pharmaceutical Co. Ltd. May 23 for a multitarget collaboration and exclusive licensing agreement for molecular glue degraders. “It is a breakthrough technology in the small-molecule drug discovery field,” Degron CEO Lily Zou told BioWorld. “People talk about cell ...
South korea | BioWorld
WEB2 days ago · June 4, 2024. By Marian (YoonJee) Chu. No Comments. Celltrion Inc., of Incheon, South Korea, gained MFDS clearance of Eydenzelt (CT-P42) as a biosimilar referencing Regeneron Pharmaceuticals Inc./Bayer AG’s Eylea (aflibercept) on May 30. The news comes on the heels of the U.S. FDA approving the first Eylea interchangeable biosimilars on May 20.
Peter Winter - BioWorld
WEBMar 17, 2021 · Feb. 10, 2021. By Peter Winter. No Comments. Biopharmaceutical companies developing cancer therapies had a productive year with about 38% of the record 53 new medicines approved by the FDA targeting oncology indications. This was one of the contributing factors for the 21% growth in the valuation of the price weighted BioWorld Cancer index in 2020.
Hybio cleared by CFDA to move into clinic with its generic
WEBOct 18, 2017 · HONG KONG – Chinese biotech company Hybio Pharmaceutical Co. recently received approval from the CFDA to conduct clinical trials for its generic version of GLP-1 analogue liraglutide. Strategics tend to invest in med-tech companies they are looking to acquire or could be acquired. Furthermore, companies like Medtronic plc and Royal Philips NV,...
Biopharma kicks off strong in 2024, raising more than $10B
WEBFeb 2, 2024 · The biopharma industry started 2024 on the upswing, with all four categories of financings tracked by BioWorld up in value compared to last January, and also up from December. In comparison to January 2023, IPO value soared 262%, follow-ons surged by 247%, public/other offerings saw a 381% rise, and private financings experienced a …
| BioWorld
WEBMar 21, 2002 · BioWorld MedTech. Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product …